

## AUTHOR CONTRIBUTION FORM

Title	Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: A phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma
First author	Thomas E. Witzig

According to the International Committee of Medical Journal Editors (ICMJE) (<u>http://www.icmje.org/ethical\_1author.html</u>):

"Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2 and 3. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship".

The responsible author of this manuscript confirms that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

**Responsible author** (author responsible for the integrity of the work as a whole)

Name: David M Goldenberg, ScD, MD

Institute: Garden State Cancer Center, Center for Molecular Medicine and Immunology, Morris Plains, NJ, USA

e-mail: dmg.gscancer@att.net

## Author contributions

Please describe the contributions of each author, indicating who was responsible for each part of the study and the preparation of the manuscript (collection of data, experiments, data analysis, generation of figures, interpretation of data, preparation of the text, etc.) :

WAW, DMG, and RMS designed the study. TEW, MBT, JGM, and EAK collected the patient data. WAW, DMG, and RMS analyzed the data. WAW, DMG, MBT, and TEW drafted the manuscript. RMS, JGM and EAK critically reviewed the manuscript. All authors approved the manuscript.